Ehrlichiosis
Ehrlichiosis is a group of intracellular bacterial infections transmitted by ticks. In the United States, Ehrlichia chaffeensis is the best-known cause of human monocytotropic ehrlichiosis. It can begin as an ordinary-looking fever and progress to severe multisystem disease—especially if effective treatment is delayed.

Bacteria that survive inside white blood cells
Ehrlichia chaffeensis is an obligate intracellular bacterium. It primarily infects mononuclear phagocytes and forms intracellular microcolonies called morulae. The lone star tick (Amblyomma americanum) is the major U.S. vector for E. chaffeensis and E. ewingii. The intracellular lifestyle helps explain why ordinary beta-lactam antibiotics that target free-growing bacteria are not effective treatment.
Fever plus low blood counts can be an important clue.
Human monocytotropic ehrlichiosis commonly causes fever, headache, fatigue, chills and muscle pain; gastrointestinal symptoms and rash can occur. Typical laboratory abnormalities include thrombocytopenia, leukopenia and elevated liver enzymes. Severe illness can include respiratory failure, kidney injury, neurologic involvement, disseminated intravascular coagulation, shock, multi-organ failure and hemophagocytic lymphohistiocytosis.
A 2024 systematic review found fever in the great majority of reported cases and frequent thrombocytopenia, leukopenia and abnormal liver tests. Immunocompromised patients were disproportionately represented among severe cases and had higher complication rates. 2024 systematic review ↗
Early negative testing does not justify waiting.
CDC recommends whole-blood PCR during the first week of illness. PCR sensitivity falls quickly after doxycycline or other effective therapy begins. Serology relies on paired IgG IFA samples; an acute sample can be negative in the first week, and a four-fold rise on a convalescent sample is stronger evidence of recent infection. IgM is not reliable for determining recent ehrlichiosis. CDC diagnostic guidance ↗
Blood smears can sometimes show morulae, but they are not sensitive enough to exclude the disease. Ehrlichia and Anaplasma antibodies can cross-react, so side-by-side testing can be useful in endemic areas.
Doxycycline is first-line for all ages.
CDC recommends doxycycline for suspected ehrlichiosis in adults and children and emphasizes that it is most effective when begun early. Treatment should not be withheld while waiting for laboratory confirmation. Fever often begins to resolve within 24–48 hours after appropriate therapy. CDC clinical care ↗
No peer-reviewed herbal regimen has been shown to treat human ehrlichiosis.
There are many internet protocols that place herbs such as Japanese knotweed, cryptolepis, cat's claw, andrographis, Chinese skullcap or houttuynia under a generic “tick-borne” umbrella. That does not establish activity against E. chaffeensis. I could not identify controlled human evidence showing that those botanicals treat ehrlichiosis, nor a robust direct pathogen-specific botanical screen comparable to the published Lyme research.
That evidence gap is useful information. It tells a reader where the scientific floor actually is. A plant can have anti-inflammatory or broad antibacterial activity and still fail to reach or kill an intracellular Ehrlichia organism in a human at a safe dose.
Why an ordinary-looking fever can become multi-organ disease
Ehrlichia chaffeensis primarily infects monocytes and macrophage-lineage cells. Intracellular replication and the immune response can disrupt normal blood-cell production and inflammatory control. That is why the disease often combines systemic symptoms with leukopenia, thrombocytopenia and elevated aminotransferases. The morulae occasionally seen on smear are colonies of organisms within a host cell, but their absence is common and does not rule out disease.
In severe ehrlichiosis, the inflammatory response can become widespread. Published cases include acute respiratory distress syndrome, acute kidney injury, meningoencephalitis, shock, disseminated intravascular coagulation, multi-organ failure and secondary hemophagocytic lymphohistiocytosis (HLH). The 2024 systematic review found complications substantially more often in immunocompromised patients.
Rash is helpful when present—but it is not required.
A rash occurs in some patients, particularly children, but ehrlichiosis can be completely rash-free. Early symptoms—fever, headache, fatigue, myalgia, nausea or diarrhea—overlap with many viral and bacterial illnesses. The combination of season, geographic exposure, tick habitat and characteristic laboratory abnormalities often raises suspicion before a confirmatory result is available.
Why a negative early antibody test is not reassuring
Antibody formation takes time. CDC notes that IgG IFA titers are often negative during the first week and recommends paired acute and convalescent samples when serology is used. In contrast, PCR detects organism DNA and is most useful early, before or soon after treatment begins. Effective antibiotics can lower the amount of circulating DNA enough to reduce PCR sensitivity within roughly 48 hours.
What if symptoms do not improve on doxycycline?
CDC says fever commonly improves within 24–48 hours. Failure to improve should make clinicians reconsider the working diagnosis, look for complications, or consider another infection such as a virus that produces a similar blood-count pattern. Heartland virus is a particularly important example in areas where lone star ticks occur because it can resemble ehrlichiosis yet will not respond to antibiotics.
Key sources
Systematic review of human monocytotropic ehrlichiosis.
Read source ↗PCR and serology timing, cross-reactivity and diagnostic limitations.
Read source ↗Doxycycline treatment and urgency of early therapy.
Read source ↗Ehrlichiosis can progress quickly. High fever, confusion, shortness of breath, severe headache, low blood pressure or rapidly worsening illness after tick exposure warrants prompt medical evaluation; clinicians may start doxycycline before test confirmation.
Products worth knowing about
Cryptolepis and artemisinin are the two products I personally used during my Babesia experience. I am sharing what I used, not prescribing a treatment. The other items are practical support products people may find useful while keeping track of medications, supplements, and hydration.
What I personally used
Cryptolepis sanguinolenta
The Cryptolepis product I personally used. See the Cryptolepis page for the research, limitations, and my experience.
View Cryptolepis on Amazon
What I personally used
Artemisinin
The artemisinin product I personally used. See the Artemisinin page for the research, limitations, and my experience.
View Artemisinin on Amazon
Practical support
Large weekly pill organizer
A simple way to keep prescriptions and supplements organized when a routine gets complicated.
View pill organizer on Amazon
Practical support
Hydration / electrolyte packets
Convenient hydration support for people who want an easy electrolyte option. This is not a Babesia treatment.
View hydration packets on Amazon